There are clear usage restrictions for crizotinib in specific populations, with particular attention to severe liver and kidney dysfunction and pregnancy status to ensure medication safety.

1. Severe liver dysfunction

1.1 Prohibited situation: Patients with severe liver dysfunction (Child Pugh C grade) are prohibited from using this product.

1.2 Basis for dose reduction: Patients with moderate to severe liver injury need to adjust the dose based on the results of liver function tests.

1.3 Monitoring suggestion: During medication, liver function indicators should be regularly monitored and adjusted in a timely manner when abnormalities occur.

2. Severe renal insufficiency

2.1 Prohibited situation: Patients with end-stage renal disease or requiring dialysis treatment are prohibited from using it.

2.2 Medication restrictions: Patients with creatinine clearance rates below 30mL/min are not recommended to use it.

2.3 Monitoring recommendations: During medication, regular checks of renal function should be conducted, and dosage adjustments should be made in case of abnormalities.

3. Pregnant patients

3.1 Prohibited situation: The use of crizotinib is prohibited during pregnancy.

3.2 Contraceptive Requirements: Women of childbearing age should take effective contraceptive measures during treatment and for at least 45 days after discontinuing medication.

3.3 Risk Disclosure: If pregnancy occurs during treatment, the patient should be informed of the potential risks to the fetus and advised to consult a specialist doctor.

4. Other taboo groups

4.1 Allergens: It is contraindicated for those who are allergic to crizotinib or its excipients.

4.2 Drug Interactions: Avoid co administration with strong CYP3A4 inducers or inhibitors to avoid affecting efficacy or increasing toxicity.